Moonlight AI Raises $3.3M for Imaging-Based Genomic Diagnostics

Swiss innovator Moonlight AI has successfully closed a $3.3 million ( €2.8 million) Seed funding round, signaling a significant advancement in diagnostic technology. The capital infusion was co-led by prominent investors Lotus One Investment, VP Venture Partners, and MEDIN Fund, with crucial participation from N&V Capital and existing supporter QAI Ventures. This funding is earmarked to propel the company's mission of transforming routine blood and cytology imaging into accessible genomic insights.

The core of Moonlight AI's disruptive approach lies in its proprietary software, which leverages advanced computer vision and artificial intelligence to detect genomic biomarkers and intricate disease signatures directly from standard imaging of blood and cytology smears. This capability bypasses the often costly and time-consuming processes associated with traditional genomic sequencing, such as Next-Generation Sequencing (NGS). The company's technology aims to democratize precision oncology by providing faster, more actionable data to clinicians.

Christian Ruiz, CEO and co-founder, emphasized the practical impact of their solution: "Our technology enables labs to generate actionable, immediate results from slides they already use in their core workflows. By removing the need for expensive hardware or manual processes, we are empowering labs to scale their diagnostic capacity and deliver faster results to patients." This efficiency gain is particularly critical in oncology, where rapid diagnosis directly influences treatment efficacy and patient outcomes.

The newly acquired funds will be instrumental in expanding Moonlight AI's unique data library. This library is distinguished by its pioneering linkage of whole slide imaging from cytopathology samples with high-fidelity genomic data. Nicole H. Romano, CTO and co-founder, highlighted the collaborative effort behind this dataset: "By collaborating with an international consortium of clinical partners, we are curating a dataset that is poised to support model robustness across real-world laboratory settings and patient populations." This robust dataset is foundational for training AI models that perform reliably across diverse clinical environments.

With this strategic investment, Moonlight AI is set to accelerate its development of diagnostic solutions for challenging conditions including myelodysplastic syndrome (MDS), non-small cell lung cancer, and chronic lymphocytic leukemia (CLL). The company also plans to bolster its team and expedite its journey toward commercialization and securing regulatory approvals. This expansion is further supported by Moonlight AI's recent transition to a Swiss Stock Corporation (Aktiengesellschaft), a move designed to facilitate its international growth strategy and market penetration.

The broader implications for the healthcare diagnostics sector are substantial. As the demand for personalized medicine grows, the bottleneck of genomic data acquisition needs to be addressed. Moonlight AI's innovative use of existing imaging infrastructure offers a scalable and cost-effective alternative, potentially reshaping how genomic information is integrated into routine clinical practice. Dr. Stefan Habringer, Chief Medical Officer and co-founder, extended an invitation for further collaboration: "The success of AI‑based diagnostics depends fundamentally on the quality and diversity of clinical data. We are therefore opening our consortium to additional hospitals and laboratories interested in shaping the next generation of diagnostics."